ASCO GU 2020 Prostate Cancer - Results from #60

Viewing 61-80 of 92 articles

ASCO GU 2020: Metastasis-Directed Therapy: Are We Changing Outcomes That Matter?

ASCO GU 2020: Time to Second Progression in Patients from TITAN with Metastatic Castration-Sensitive Prostate Cancer by First Subsequent Therapy (Hormone v Taxane)

ASCO GU 2020: The Deleterious Association Between Proton Pump Inhibitors and Prostate Cancer Specific Death

ASCO GU 2020: The Effect of Deep AR Suppression with Enzalutamide or Apalutamide on Endogenous Glucocorticoids: Implications for Adverse Effects and Development of Combination Therapies

ASCO GU 2020: Clinical Outcomes and Patient Profiles in REASSURE: An Observational Study of Radium-223 in Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: (CARD) Pain Response and Health-Related Quality of Life Analysis in Patients with Metastatic Castration-Resistant Prostate Cancer

ASCO GU 2020: Targeted Therapy in the Context of Low Volume Metastatic Prostate Cancer

ASCO GU 2020: KEYNOTE-199: Pembrolizumab Plus Enzalutamide for Enzalutamide-Resistant mCRPC: Cohorts 4-5

ASCO GU 2020: Response to Olaparib or Carboplatin in a Real-World Cohort of Men with DNA Damage Repair DDR Deficient Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2020: Biologic and Clinical Rationale for Treatment of the Primary in Low-Volume Metastatic Disease

ASCO GU 2020: Next-Generation Sequencing of Tumor Tissue from >4000 Men with Metastatic Castration-Resistant Prostate Cancer: The PROfound Phase III Study Experience

ASCO GU 2020: Individualized Approaches to Treatment in Localized Prostate Cancer

ASCO GU 2020: Luminal B Subtype as a Predictive Biomarker of Docetaxel Benefit for Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer: A Correlative Study of E3805 CHAARTED

ASCO GU 2020: Time to Second Progression in Patients from TITAN with Metastatic Castration-Sensitive Prostate Cancer by First Subsequent Therapy (hormonal vs. taxane)

ASCO GU 2020: Transcriptome Profiling of NRG Oncology/RTOG 9601: Validation of a Prognostic Genomic Classifier in Salvage Radiotherapy Prostate Cancer Patients from a Prospective Randomized Trial

ASCO GU 2020: Beyond Standard Imaging: Defining Extent of Disease Using Novel Approaches

ASCO GU 2020: Clinical outcomes and Patient profiles in REASSURE: An Observational Study of Radium-223 (Ra-223) in Metastatic Castration-Resistant Prostate Cancer (mCRPC)

ASCO GU 2020: (STOMP): Five-year Results of a Randomized Phase II Trial

ASCO GU 2020: Concurrent or Layered Treatment with Radium-223 and Enzalutamide or Abiraterone Plus Prednisone/Prednisolone: A Retrospective Study of Real-World Clinical Outcomes in Patients with mCRPC

ASCO GU 2020: Analysis of Small Non-Coding RNAs in Urinary Exosomes to Classify Prostate Cancer into Low-Grade (GG1) and Higher-Grade (GG2-5)

1
2
3
4
5